Pernix Therapeutics Hldgs buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 07.12.15 mit einem Endkurs von 25,98 € beendet. Die Einschätzung zu Pernix Therapeutics Hldgs enttäuschte mit einer Rendite von -14,29 %. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Pernix Therapeutics Hldgs | - | - | - | - |
| iShares Core DAX® | 0,99 % | 8,31 % | 7,03 % | 49,79 % |
| iShares Nasdaq 100 | 2,07 % | 16,77 % | 35,95 % | 96,63 % |
| iShares Nikkei 225® | 2,27 % | 15,61 % | 46,57 % | 69,05 % |
| iShares S&P 500 | 1,04 % | 11,08 % | 26,46 % | 68,09 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion Pernix Therapeutics Hldgs diskutieren
PTX is too cheap given its growth prospects and earnings trajectory!
Pernix Therapeutics (NASDAQ:PTX) is just one of a myriad small pharmaceuticals that have seen their stocks under pressure due to the fallout and collapse of Valeant Pharmaceuticals. After a big decline in its shares, the company reported blowout quarterly results this week.
At just $3.25 a share, the stock is too cheap given its growth prospects and earnings trajectory.
Earning Highlights: Pernix posted earnings of eight cents a share, seven cents a share above the consensus.Revenues climbed almost 55% year-over-year to just under $49 million for the quarter, just under $2 million above the consensus.Adjusted EBITDA increased to $8.7 million, compared to just under $7 million during the prior year period.
The company has three core products, Silenor, Treximit and Zohydro, that all have good growth prospects and decent patent expirations.